Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
Revolutionary ovarian cancer rapid test available Q4 2022
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The company exports mobile surgery equipment to over 100 countries from Pune
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Subscribe To Our Newsletter & Stay Updated
